Skip to main content
Erschienen in: Die Dermatologie 1/2019

05.12.2018 | Atopische Dermatitis | CME

Immunadsorption in der Dermatologie

verfasst von: Franziska Hübner, Michael Kasperkiewicz, Detlef Zillikens, Prof. Dr. med. Dr. rer. nat. Enno Schmidt

Erschienen in: Die Dermatologie | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Den blasenbildenden Autoimmundermatosen liegen pathogenetisch relevante Autoantikörper gegen Bestandteile der Epidermis und/oder oberflächennahen Schleimhäute (beim Pemphigus) bzw. gegen Strukturproteine der dermoepidermalen Junktionszone (bei den Pemphigoiderkrankungen) zugrunde. Mittels Immunadsorption (IA) können Antikörper aus dem Plasma entfernt werden. Daten zum adjuvanten Einsatz dieser Therapie in der Dermatologie liegen insbesondere für Patienten mit einem therapierefraktären oder schweren Pemphigus vulgaris und Pemphigus foliaceus, aber auch mit Pemphigoiderkrankungen vor. In den letzten Jahren wurden zudem verschiedene Therapieprotokolle für den Einsatz der IA bei Patienten mit schwerem atopischem Ekzem und erhöhten IgE-Spiegeln publiziert. Während hauptsächlich Panimmunglobulinadsorber bzw. bei der atopischen Dermatitis auch ein spezifischer Ig(Immunglobulin)E-Adsorber eingesetzt wurden, sind in Zukunft antigenspezifische Adsorber zu erwarten, die eine gezielte Reduktion der Autoantikörper ermöglichen.
Literatur
1.
Zurück zum Zitat Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D (2012) Immunoadsorption in dermatology. Ther Apher Dial 16:311–320CrossRef Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D (2012) Immunoadsorption in dermatology. Ther Apher Dial 16:311–320CrossRef
2.
Zurück zum Zitat Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189–1196CrossRef Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189–1196CrossRef
3.
Zurück zum Zitat Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB (1992) Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 90:1628–1633CrossRef Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB (1992) Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 90:1628–1633CrossRef
4.
Zurück zum Zitat Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C et al (2017) Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease. J Invest Dermatol 137:1709–1718CrossRef Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C et al (2017) Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease. J Invest Dermatol 137:1709–1718CrossRef
5.
Zurück zum Zitat Holtsche MM, Zillikens D, Schmidt E (2018) Mucous membrane pemphigoid. Hautarzt 69:67–83CrossRef Holtsche MM, Zillikens D, Schmidt E (2018) Mucous membrane pemphigoid. Hautarzt 69:67–83CrossRef
6.
Zurück zum Zitat Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS et al (2017) Pemphigus. Nat Rev Dis Primers 3:17026CrossRef Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS et al (2017) Pemphigus. Nat Rev Dis Primers 3:17026CrossRef
7.
Zurück zum Zitat Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E et al (2016) Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options. J Invest Dermatol 136:24–33CrossRef Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E et al (2016) Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options. J Invest Dermatol 136:24–33CrossRef
8.
Zurück zum Zitat Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA et al (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480–2488CrossRef Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA et al (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480–2488CrossRef
9.
Zurück zum Zitat Schulze F, Kasperkiewicz M, Zillikens D, Schmidt E (2013) Bullous pemphigoid. Hautarzt 64:931–943 (quiz 944–5)CrossRef Schulze F, Kasperkiewicz M, Zillikens D, Schmidt E (2013) Bullous pemphigoid. Hautarzt 64:931–943 (quiz 944–5)CrossRef
10.
Zurück zum Zitat Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS et al (1984) Plasma exchange in bullous pemphigoid. Lancet 2:486–488CrossRef Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS et al (1984) Plasma exchange in bullous pemphigoid. Lancet 2:486–488CrossRef
11.
Zurück zum Zitat Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B et al (1993) Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 129:49–53CrossRef Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B et al (1993) Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 129:49–53CrossRef
12.
Zurück zum Zitat Schoen H, Foedinger D, Derfler K, Amann G, Rappersberger K, Stingl G et al (1998) Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 134:706–710CrossRef Schoen H, Foedinger D, Derfler K, Amann G, Rappersberger K, Stingl G et al (1998) Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 134:706–710CrossRef
13.
Zurück zum Zitat Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M et al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881–887CrossRef Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M et al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881–887CrossRef
14.
Zurück zum Zitat Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241–253CrossRef Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241–253CrossRef
15.
Zurück zum Zitat Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382–388CrossRef Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382–388CrossRef
16.
Zurück zum Zitat Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J et al (2012) Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 166:154–160CrossRef Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J et al (2012) Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 166:154–160CrossRef
17.
Zurück zum Zitat Kasperkiewicz M, Mook S‑C, Knuth-Rehr D, Vorobyev A, Ludwig RJ, Zillikens D et al (2018) IgE-selective Immunoadsorption for severe atopic dermatitis. Front Med (Lausanne) 5:27CrossRef Kasperkiewicz M, Mook S‑C, Knuth-Rehr D, Vorobyev A, Ludwig RJ, Zillikens D et al (2018) IgE-selective Immunoadsorption for severe atopic dermatitis. Front Med (Lausanne) 5:27CrossRef
18.
Zurück zum Zitat Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M et al (2011) Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 127:267–270.e1–6CrossRef Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M et al (2011) Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 127:267–270.e1–6CrossRef
19.
Zurück zum Zitat Hübner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hübner J, Süfke S, et al (2018) Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges 16(9):1109–1119PubMed Hübner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hübner J, Süfke S, et al (2018) Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges 16(9):1109–1119PubMed
20.
Zurück zum Zitat Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320–332CrossRef Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320–332CrossRef
21.
Zurück zum Zitat Schmidt E, Zillikens D (2011) The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 108:399–405, I–IIIPubMedPubMedCentral Schmidt E, Zillikens D (2011) The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 108:399–405, I–IIIPubMedPubMedCentral
22.
Zurück zum Zitat Schmidt E, Obe K, Bröcker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174–178CrossRef Schmidt E, Obe K, Bröcker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174–178CrossRef
23.
Zurück zum Zitat Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H et al (2015) S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 13:833–844PubMed Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H et al (2015) S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 13:833–844PubMed
24.
Zurück zum Zitat Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S et al (1997) Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159:2010–2017PubMed Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S et al (1997) Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159:2010–2017PubMed
25.
Zurück zum Zitat Schmidt E, Dähnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S et al (2010) Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 19:458–463CrossRef Schmidt E, Dähnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S et al (2010) Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 19:458–463CrossRef
26.
Zurück zum Zitat Hahn-Ristic K, Rzany B, Amagai M, Bröcker EB, Zillikens D (2002) Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol 16:68–71CrossRef Hahn-Ristic K, Rzany B, Amagai M, Bröcker EB, Zillikens D (2002) Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol 16:68–71CrossRef
27.
Zurück zum Zitat Bertram F, Bröcker E‑B, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 7:434–440PubMed Bertram F, Bröcker E‑B, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 7:434–440PubMed
28.
Zurück zum Zitat Hübner F, Recke A, Zillikens D, Linder R, Schmidt E (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 136:2495–2498CrossRef Hübner F, Recke A, Zillikens D, Linder R, Schmidt E (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 136:2495–2498CrossRef
29.
Zurück zum Zitat Bystryn JC, Steinman NM (1996) The adjuvant therapy of pemphigus. An update. Arch Dermatol 132:203–212CrossRef Bystryn JC, Steinman NM (1996) The adjuvant therapy of pemphigus. An update. Arch Dermatol 132:203–212CrossRef
30.
Zurück zum Zitat Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J (2008) Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ 337:a180CrossRef Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J (2008) Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ 337:a180CrossRef
31.
Zurück zum Zitat Kasperkiewicz M, Schmidt E (2009) Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 6:270–280CrossRef Kasperkiewicz M, Schmidt E (2009) Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 6:270–280CrossRef
32.
Zurück zum Zitat Martin LK, Werth VP, Villaneuva EV, Murrell DF (2011) A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 64:903–908CrossRef Martin LK, Werth VP, Villaneuva EV, Murrell DF (2011) A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 64:903–908CrossRef
33.
Zurück zum Zitat Ahmed AR, Shetty S (2015) A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 14:323–331CrossRef Ahmed AR, Shetty S (2015) A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 14:323–331CrossRef
34.
Zurück zum Zitat Schmidt E, Bröcker E‑B, Goebeler M (2008) Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 34:56–64CrossRef Schmidt E, Bröcker E‑B, Goebeler M (2008) Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 34:56–64CrossRef
35.
Zurück zum Zitat Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031–2040CrossRef Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031–2040CrossRef
36.
Zurück zum Zitat Schmidt E (2017) Rituximab as first-line treatment of pemphigus. Lancet 389:1956–1958CrossRef Schmidt E (2017) Rituximab as first-line treatment of pemphigus. Lancet 389:1956–1958CrossRef
38.
Zurück zum Zitat Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M et al (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222–1229CrossRef Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M et al (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222–1229CrossRef
39.
Zurück zum Zitat Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Bröcker E‑B et al (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768–774CrossRef Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Bröcker E‑B et al (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768–774CrossRef
40.
Zurück zum Zitat Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598–605CrossRef Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598–605CrossRef
41.
Zurück zum Zitat Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M et al (2012) Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 166:844–852CrossRef Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M et al (2012) Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 166:844–852CrossRef
42.
Zurück zum Zitat Schaffer C, Buclin T, Jornayvaz FR, Cazzaniga S, Borradori L, Gilliet M et al (2017) Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid. Dermatology 233:401–403CrossRef Schaffer C, Buclin T, Jornayvaz FR, Cazzaniga S, Borradori L, Gilliet M et al (2017) Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid. Dermatology 233:401–403CrossRef
43.
Zurück zum Zitat Försti A‑K, Huilaja L, Schmidt E, Tasanen K (2017) Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26:1228–1234CrossRef Försti A‑K, Huilaja L, Schmidt E, Tasanen K (2017) Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26:1228–1234CrossRef
44.
Zurück zum Zitat Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Köhl J et al (2014) Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol 184:2185–2196CrossRef Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Köhl J et al (2014) Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol 184:2185–2196CrossRef
45.
Zurück zum Zitat Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K et al (2011) Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 187:1176–1183CrossRef Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K et al (2011) Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 187:1176–1183CrossRef
46.
Zurück zum Zitat Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR et al (2007) Humanization of autoantigen. Nat Med 13:378–383CrossRef Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR et al (2007) Humanization of autoantigen. Nat Med 13:378–383CrossRef
47.
Zurück zum Zitat Schmidt E, Reimer S, Kruse N, Bröcker EB, Zillikens D (2001) The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 124:157–162CrossRef Schmidt E, Reimer S, Kruse N, Bröcker EB, Zillikens D (2001) The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 124:157–162CrossRef
48.
Zurück zum Zitat Joly P, Roujeau J‑C, Benichou J, Picard C, Dreno B, Delaporte E et al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321–327CrossRef Joly P, Roujeau J‑C, Benichou J, Picard C, Dreno B, Delaporte E et al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321–327CrossRef
49.
Zurück zum Zitat Sticherling M, Franke A, Aberer E, Gläser R, Hertl M, Pfeiffer C et al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177:1299–1305CrossRef Sticherling M, Franke A, Aberer E, Gläser R, Hertl M, Pfeiffer C et al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177:1299–1305CrossRef
50.
Zurück zum Zitat Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389:1630–1638CrossRef Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389:1630–1638CrossRef
51.
Zurück zum Zitat Försti A‑K, Jokelainen J, Timonen M, Tasanen K (2016) Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 96:758–761PubMed Försti A‑K, Jokelainen J, Timonen M, Tasanen K (2016) Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 96:758–761PubMed
52.
Zurück zum Zitat Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B et al (2002) Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 138:903–908CrossRef Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B et al (2002) Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 138:903–908CrossRef
53.
Zurück zum Zitat Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D et al (2014) Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol 71:1018–1020CrossRef Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D et al (2014) Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol 71:1018–1020CrossRef
54.
Zurück zum Zitat Kolesnik M, Becker E, Reinhold D, Ambach A, Heim MU, Gollnick H et al (2014) Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol 28:771–780CrossRef Kolesnik M, Becker E, Reinhold D, Ambach A, Heim MU, Gollnick H et al (2014) Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol 28:771–780CrossRef
55.
Zurück zum Zitat Müller PA, Bröcker EB, Klinker E, Stoevesandt J, Benoit S (2012) Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 224:224–227CrossRef Müller PA, Bröcker EB, Klinker E, Stoevesandt J, Benoit S (2012) Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 224:224–227CrossRef
56.
Zurück zum Zitat Kasperkiewicz M, Meier M, Zillikens D, Schmidt E (2010) Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 220:259–263CrossRef Kasperkiewicz M, Meier M, Zillikens D, Schmidt E (2010) Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 220:259–263CrossRef
57.
Zurück zum Zitat Recke A, Shimanovich I, Steven P, Westermann L, Zillikens D, Schmidt E (2011) Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab. Hautarzt 62:852–858CrossRef Recke A, Shimanovich I, Steven P, Westermann L, Zillikens D, Schmidt E (2011) Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab. Hautarzt 62:852–858CrossRef
58.
Zurück zum Zitat Kasperkiewicz M, Hoppe U, Zillikens D, Schmidt E (2010) Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol 35:614–617CrossRef Kasperkiewicz M, Hoppe U, Zillikens D, Schmidt E (2010) Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol 35:614–617CrossRef
59.
Zurück zum Zitat Westermann L, Hügel R, Meier M, Weichenthal M, Zillikens D, Gläser R et al (2012) Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol 39:168–171CrossRef Westermann L, Hügel R, Meier M, Weichenthal M, Zillikens D, Gläser R et al (2012) Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol 39:168–171CrossRef
60.
Zurück zum Zitat Wöhrl S, Geusau A, Karlhofer F, Derfler K, Stingl G, Zillikens D (2003) Pemphigoid gestationis: treatment with immunoapheresis. J Dtsch Dermatol Ges 1:126–130CrossRef Wöhrl S, Geusau A, Karlhofer F, Derfler K, Stingl G, Zillikens D (2003) Pemphigoid gestationis: treatment with immunoapheresis. J Dtsch Dermatol Ges 1:126–130CrossRef
61.
Zurück zum Zitat Marker M, Derfler K, Monshi B, Rappersberger K (2011) Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J Dtsch Dermatol Ges 9:27–31PubMed Marker M, Derfler K, Monshi B, Rappersberger K (2011) Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J Dtsch Dermatol Ges 9:27–31PubMed
62.
Zurück zum Zitat Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K et al (2007) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 143:192–198CrossRef Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K et al (2007) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 143:192–198CrossRef
63.
Zurück zum Zitat Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ (1995) Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol 155:5449–5454PubMed Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ (1995) Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol 155:5449–5454PubMed
64.
Zurück zum Zitat Kubisch I, Diessenbacher P, Schmidt E, Gollnick H, Leverkus M (2010) Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol 11:289–293PubMed Kubisch I, Diessenbacher P, Schmidt E, Gollnick H, Leverkus M (2010) Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol 11:289–293PubMed
65.
Zurück zum Zitat Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD (2018) Atopic dermatitis. Nat Rev Dis Primers 4:1CrossRef Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD (2018) Atopic dermatitis. Nat Rev Dis Primers 4:1CrossRef
66.
Zurück zum Zitat Weidinger S, Novak N (2016) Atopic dermatitis. Lancet 387:1109–1122CrossRef Weidinger S, Novak N (2016) Atopic dermatitis. Lancet 387:1109–1122CrossRef
67.
Zurück zum Zitat Wang H‑H, Li Y‑C, Huang Y‑C (1722) Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 138:1719–e1CrossRef Wang H‑H, Li Y‑C, Huang Y‑C (1722) Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 138:1719–e1CrossRef
68.
Zurück zum Zitat Kasperkiewicz M, Schmidt E, Ludwig RJ, Zillikens D (2018) Targeting IgE antibodies by Immunoadsorption in atopic dermatitis. Front Immunol 9:254CrossRef Kasperkiewicz M, Schmidt E, Ludwig RJ, Zillikens D (2018) Targeting IgE antibodies by Immunoadsorption in atopic dermatitis. Front Immunol 9:254CrossRef
69.
Zurück zum Zitat Daeschlein G, Scholz S, Lutze S, Eming R, Arnold A, Haase H et al (2015) Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis. Ther Apher Dial 19:279–287CrossRef Daeschlein G, Scholz S, Lutze S, Eming R, Arnold A, Haase H et al (2015) Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis. Ther Apher Dial 19:279–287CrossRef
70.
Zurück zum Zitat Kasperkiewicz M, Süfke S, Schmidt E, Zillikens D (2014) IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatol 150:1350–1351CrossRef Kasperkiewicz M, Süfke S, Schmidt E, Zillikens D (2014) IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatol 150:1350–1351CrossRef
71.
Zurück zum Zitat Reich K, Deinzer J, Fiege A‑K, von Gruben V, Sack A‑L, Thraen A et al (1884) Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. J Allergy Clin Immunol 137:1882–e6CrossRef Reich K, Deinzer J, Fiege A‑K, von Gruben V, Sack A‑L, Thraen A et al (1884) Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. J Allergy Clin Immunol 137:1882–e6CrossRef
72.
Zurück zum Zitat Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V et al (2016) Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 96:72–76CrossRef Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V et al (2016) Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 96:72–76CrossRef
73.
Zurück zum Zitat Mersmann M, Dworschak J, Ebermann K, Komorowski L, Schlumberger W, Stöcker W et al (2016) Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Arch Dermatol Res 308:31–38CrossRef Mersmann M, Dworschak J, Ebermann K, Komorowski L, Schlumberger W, Stöcker W et al (2016) Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Arch Dermatol Res 308:31–38CrossRef
74.
Zurück zum Zitat Langenhan J, Dworschak J, Saschenbrecker S, Komorowski L, Schlumberger W, Stöcker W et al (2014) Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol 23:253–259CrossRef Langenhan J, Dworschak J, Saschenbrecker S, Komorowski L, Schlumberger W, Stöcker W et al (2014) Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol 23:253–259CrossRef
Metadaten
Titel
Immunadsorption in der Dermatologie
verfasst von
Franziska Hübner
Michael Kasperkiewicz
Detlef Zillikens
Prof. Dr. med. Dr. rer. nat. Enno Schmidt
Publikationsdatum
05.12.2018
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 1/2019
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-018-4315-2

Weitere Artikel der Ausgabe 1/2019

Die Dermatologie 1/2019 Zur Ausgabe